Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Hospitalization time 7% Improvement Relative Risk Viral clearance time 55% c19favipiravir.com Shinada et al. Favipiravir for COVID-19 LATE Favors favipiravir Favors control
Shinada, 34 patient favipiravir late treatment study: 7% shorter hospitalization [p=0.84] and 55% faster viral clearance [p=0.04] https://c19p.org/shinada
copied to clipboard
Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir
Shinada et al., Viruses, doi:10.3390/v14040670
24 Mar 2022    Source   PDF   Share   Tweet
Retrospective 17 COVID+ patients treated with favipiravir and 17 matched controls in Japan, showing faster viral clearance with treatment. Favipiravir 3600mg day one, 1600mg per day for up to 14 days.
hospitalization time, 7.5% lower, HR 0.93, p = 0.84, treatment 17, control 17.
viral clearance time, 55.2% lower, HR 0.45, p = 0.04, treatment 17, control 17.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shinada et al., 24 Mar 2022, retrospective, Japan, peer-reviewed, 11 authors, study period 28 May, 2020 - 26 September, 2020, average treatment delay 8.9 days.
Contact: takashisato1220@gmail.com (corresponding author), kanakoshinada7@gmail.com, mshinopy@gmail.com, shin.ohta0915@gmail.com, miwapicco@outlook.jp, shinkai050169@gmail.com, m-mine@marianna-u.ac.jp, sayamrym@niid.go.jp, yuadachi@niid.go.jp, matt@niid.go.jp, ytakahas@niid.go.jp.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit